XGN / Exagen Inc. (XGN) CEO John Aballi on Q3 2022 Results - Earnings Call Transcript

Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $ more_horizontal

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial r more_horizontal

Exagen Inc. (NASDAQ:XGN ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi more_horizontal

Exagen Inc. (XGN) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $ more_horizontal

The stock price of Exagen Inc (NASDAQ: XGN) fell by 14.89% after hours in the most recent trading session. This is why. more_horizontal

Exagen Inc. (NASDAQ:XGN ) Q4 2022 Results Conference Call March 20, 2023 4:30 PM ET Company Participants Ryan Douglas - Investor Relations John Aballi more_horizontal

Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hol more_horizontal

Exagen Inc. (NASDAQ:XGN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President more_horizontal